RxDoctor Payments DataLook up a doctor →

Cynthia Ronan, MD

Obstetrics & Gynecology · Derby, CTNPI 1346251659

Payments from drug & device makers

$10,016in general payments, 2019–2025

Across 521 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exeltis, USA Inc.$3K
  • AbbVie$1K
  • Astellas Pharma US Inc$824
  • Mayne Pharma Commercial LLC$681
  • Sumitomo Pharma America, Inc.$665
  • Pfizer$553
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$9,971100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,016 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.

See all obstetrics & gynecology providers in Connecticut

Medicare billing

Part B allowed, 2024
$15,200
Medicare patients
56
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron15$17,780
MyrbetriqMirabegron11$14,952
PremarinEstrogens, Conjugated32$9,153
ValacyclovirValacyclovir Hcl26$1,675
Estradiol39$1,354
Raloxifene Hcl18$965
Metronidazole17$558
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$522
Medroxyprogesterone Acetate21$471
Nystatin14$264
Fluconazole23$149
Terconazole11$141
Zolpidem Tartrate13$131
Ibuprofen12$37
Alprazolam17$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$665$17,78015 claims
Astellas Pharma US IncMyrbetriq$824$14,95211 claims
PfizerPremarin$553$9,15332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.

Other obstetrics & gynecology in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →